CareTrust REIT, Inc. (CTRE) — closed signal from March 6, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 4, 2026.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published March 6, 2026
CareTrust looks like a lower-risk pick for the next few months. Recent analyst support, clearer guidance from the company, and more investment activity make the business outlook steadier than many rebound candidates. The stock fell sharply and needs time to prove a durable rise, so it is most appealing near the lower price range for income and modest growth.
Primary drivers
- Analyst support and clearer company guidance
- Expanding healthcare properties should add revenue
- Recent selling makes entry less risky near support
- Reliable income from assets helps in choppy markets
How it played out
CTRE: thesis peaked near target, then faded
Lyra published CTRE at $39.18 on March 6, 2026, with 10% expected growth over the short term. The thesis pointed to analyst support, clearer company guidance, expanding healthcare properties, recent selling near support, and reliable income from assets in choppy markets.
Inside the window, CTRE rose to $43.08 on May 14, 2026, with a 10% peak gain. The target was $43.10, and the stock stayed below it. By June 4, 2026, it ended at $37.44. The thesis partially played out, but it did not reach the published target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.